Design Therapeutics, Inc.
DSGN · Pharmaceutical Preparations · 62.5M shares · +7%/yr ↑ dilution · EDGAR filings ↗
Reference price $5.25 · est. market cap ~$328M — last insider sale, 2025-08-13 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D46Clinical/early-stage biotech — genetic-disease clinical, very cash-rich.
Strengths
- Liquidity — current ratio 17.1 (93rd)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Exec changeRecent 8-K item 5.02 8-K ↗
- Cash burnNegative free cash flow (-54.6M)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Strong balance sheetStrong balance sheet — $220M cash & investments, ~16 quarters of runway
- Notable holderHeld by 5 notable fund(s): FMR LLC, STATE STREET CORP, GOLDMAN SACHS GROUP INC +2 more (as of 2026-03-31)
- Trial readout soonUpcoming trial readout ~2026-09 — PHASE2 · Fuchs Endothelial Corneal Dystrophy
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Return on equity
-32.8%
Return on assets
-30.9%
Current ratio
17.1×
Free cash flow
-$55M
Tangible book value
$213M
Cash & investments
$220M
Cash runway
16q
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2025-08-13 | William Arsani | Sell | 345K | $5.25 |
| 2025-08-13 | William Arsani | Sell | 218K | $5.25 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06874010 ↗ | A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia Friedreich Ataxia | PHASE1/PHASE2 | Recruiting | 2026-12-01 |
| NCT07024693 ↗ | DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy Fuchs Endothelial Corneal Dystrophy, Fuchs | PHASE2 | Recruiting | 2026-09-01 |
| NCT06772870 ↗ | A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participants Friedreich Ataxia | PHASE1 | Not Yet Recruiting | 2025-09-01 |
| NCT05573698 ↗ | Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia Friedreich Ataxia | PHASE1 | Completed | 2023-08-25 |
| NCT05285540 ↗ | Study to Evaluate DT-216 in Adult Patients With Friedreich Ataxia Friedreich Ataxia | PHASE1 | Completed | 2022-12-19 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-11 | 2026-06-09 | 0001193125-26-267485 ↗ |
| 8-K | 2026-05-18 | 2026-05-18 | 0001193125-26-227875 ↗ |
| 10-Q | 2026-04-28 | 2026-03-31 | 0001193125-26-187063 ↗ |
| 8-K | 2026-04-28 | 2026-04-28 | 0001193125-26-187012 ↗ |
| 8-K | 2026-04-01 | 2026-03-31 | 0001193125-26-137861 ↗ |
| 8-K | 2026-03-09 | 2026-03-09 | 0001193125-26-098474 ↗ |
| 10-K | 2026-03-09 | 2025-12-31 | 0001193125-26-098491 ↗ |
| 8-K | 2026-01-30 | 2026-01-29 | 0001193125-26-031772 ↗ |
| 8-K | 2025-11-05 | 2025-11-05 | 0001193125-25-266933 ↗ |
| 10-Q | 2025-11-05 | 2025-09-30 | 0001193125-25-266970 ↗ |
| 8-K | 2025-09-10 | 2025-09-09 | 0001807120-25-000004 ↗ |
| 8-K | 2025-08-07 | 2025-08-07 | 0000950170-25-105008 ↗ |